Drug Profile
Amblyomin-X
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Uniao Quimica Farmaceutica
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Solid-tumours in Brazil (IV)
- 25 Apr 2017 União Química Farmacêutica Nacional plans a phase I trial for Solid tumours (Second-line therapy or greater) in Brazil (NCT03120130)
- 29 Mar 2017 Preclinical trials in Solid tumours in Brazil (IV)